Search bioRxiv⌕ Search

Biology subjects

Remes, P.

Publications and source records attributed to Remes, P..

2 recordsLinked to original sources

Revisiting resonance-excitation collision-induced dissociation for data-independent acquisition

Data-independent acquisition (DIA) proteomics relies almost exclusively on beam-type collision-induced dissociation (HCD) because its short activation time supports fast acquisition rates required for DIA. However, HCD requires charge state calibration and is therefore imperfect for mixed-charge DIA isolation windows. Resonance-excitation collision-induced dissociation (reCID) offers a promising alternative to HCD for DIA because the ion activation is effectively independent of charge state. Historically, reCIDs longer activation time has been considered too slow for DIA. Here, we revisit reCID for DIA proteomics using a modified Orbitrap Tribrid Apex MultiOmics mass spectrometer (Apex) that recovers acquisition-matrix overhead as additional ion injection time, enabling reCID acquisition rates comparable to HCD. Using matched acquisition rate settings of tryptic HeLa digests, reCID achieved precursor and protein detections similar to HCD when used with Carafe fine-tuned, fragmentation-matched spectral libraries. Library fine-tuning improved reCID precursor detections more than HCD detections, 24% versus 5%, indicating that HCD-trained prediction models are suboptimal for reCID spectra. ReCID also maintained peptide-level quantitative performance, including ions measured per peptide, precision, and accuracy. Across seven NCI cancer cell lines and pooled mixtures, protein abundance rankings were highly conserved between the Apex reCID and HCD methods, and also across Orbitrap Astral Zoom platforms. These results support reCID as a practical fragmentation mode for DIA proteomics.

biochemistry↗

A novel hybrid high speed mass spectrometer allows rapid translation from biomarker candidates to targeted clinical tests using 15N labeled proteins

Recent developments in affinity binder or mass spectrometry (MS)-based plasma proteomics are now producing panels of potential biomarker candidates for diagnosis or prognosis. However, clinical validation and implementation of these biomarkers remain limited by the reliance on dated triple quadrupole MS technology. Here, we evaluate a novel hybrid high-speed mass spectrometer, Stellar MS, which integrates the robustness of triple quadrupoles with the enhanced capabilities of an advanced linear ion trap analyzer. This instrument allows for extremely rapid and sensitive parallel reaction monitoring (PRM) and MS3 targeting. The Stellar MS allowed targeting thousands of peptides originally measured on Orbitrap Astral MS, achieving high reproducibility and low coefficients of variation (CV) as well as sensitivity and specificity sufficient for more than the top 1000 plasma proteins. Furthermore, we developed targeted assays for alcohol-related liver disease (ALD) biomarkers, showcasing the potential of Stellar MS in clinical applications. Absolute quantification is typically a requirement for clinical assays and we explore the use of 15 N labeled protein standards in a rapid, streamlined and generic manner. Our results indicate that Stellar MS can bridge the gap between proteomics discovery and routine clinical testing, enhancing the diagnostic and prognostic utility of protein biomarkers.

biochemistry↗